ES2422204T3 - Novedosos derivados de imidazolidin-2-ona como moduladores selectivos de receptor de andrógenos (SARMS) - Google Patents

Novedosos derivados de imidazolidin-2-ona como moduladores selectivos de receptor de andrógenos (SARMS)

Info

Publication number
ES2422204T3
ES2422204T3 ES05800947T ES05800947T ES2422204T3 ES 2422204 T3 ES2422204 T3 ES 2422204T3 ES 05800947 T ES05800947 T ES 05800947T ES 05800947 T ES05800947 T ES 05800947T ES 2422204 T3 ES2422204 T3 ES 2422204T3
Authority
ES
Spain
Prior art keywords
4alkyl
halogen
amino
substituted
4alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES05800947T
Other languages
English (en)
Inventor
James C Lanter
Zhihua Sui
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Application granted granted Critical
Publication of ES2422204T3 publication Critical patent/ES2422204T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30Oxygen or sulfur atoms
    • C07D233/32One oxygen atom
    • C07D233/34Ethylene-urea
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16Masculine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26Androgens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28Antiandrogens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gynecology & Obstetrics (AREA)
  • AIDS & HIV (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un compuesto de fórmula (I) **Fórmula** R1 es hidrógeno; R2 es alquilo C1-4 o alquilo C1-4 sustituido con halógeno y R3 es carboxi, -C(O)-(C1-4 alcoxi), -C(O)-N(RB)2; en la que cada RB está independientemente seleccionado de hidrógeno, alquilo C1-4 y arilo, a condición de quesi está presente, solo un RB es arilo; en la que el arilo está opcionalmente sustituido con uno o más sustituyentes independientementeseleccionados de halógeno, hidroxi, carboxi, alquilo C1-4, alquilo C1-4 sustituido con halógeno, alcoxi C1-4, alcoxiC1-4 sustituido con halógeno, ciano, nitro, amino, alquil C1-4-amino o di(alquil C1-4)amino; R4 está seleccionado del grupo que consiste en halógeno, hidroxi, carboxi, alquilo C1-4, alquilo C1-4 sustituidocon halógeno, alcoxi C1-4, alcoxi C1-4 sustituido con halógeno, ciano, nitro, amino, alquil C1-4-amino, di(alquil C1-4)amino, -C(O)-(alquilo C1-4), -C(O)-(alcoxi C1-4), -C(O)-N(RA)2, -S(O)0-2-(alquilo C1-4), -SO2-N(RA)2, -N(RA)-C(O)-(alquilo C1-4), -N(RA)-C(O)(alquilo C1-4 sustituido con halógeno) y arilo; en la que cada RA está independientemente seleccionado de hidrógeno o alquilo C1-4; en la que el arilo está opcionalmente sustituido con uno o más sustituyentes independientementeseleccionados de halógeno, hidroxi, carboxi, alquilo C1-4, alquilo C1-4 sustituido con halógeno, alcoxi C1-4, alcoxiC1-4 sustituido con halógeno, ciano, nitro, amino, alquil C1-4-amino o di(alquil C1-4)amino; a es un número entero de 0 a 4; b es 0; o una sal farmacéuticamente aceptable del mismo.
ES05800947T 2004-09-10 2005-09-09 Novedosos derivados de imidazolidin-2-ona como moduladores selectivos de receptor de andrógenos (SARMS) Active ES2422204T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60915704P 2004-09-10 2004-09-10
PCT/US2005/032381 WO2006031715A2 (en) 2004-09-10 2005-09-09 Novel imidazolidin-2-one derivatives as selective androgen receptor modulators (sarms)

Publications (1)

Publication Number Publication Date
ES2422204T3 true ES2422204T3 (es) 2013-09-09

Family

ID=36060597

Family Applications (1)

Application Number Title Priority Date Filing Date
ES05800947T Active ES2422204T3 (es) 2004-09-10 2005-09-09 Novedosos derivados de imidazolidin-2-ona como moduladores selectivos de receptor de andrógenos (SARMS)

Country Status (8)

Country Link
US (2) US7531565B2 (es)
EP (1) EP1791821B1 (es)
JP (1) JP5031568B2 (es)
CN (1) CN101056862B (es)
AU (1) AU2005285035B2 (es)
CA (1) CA2579514A1 (es)
ES (1) ES2422204T3 (es)
WO (1) WO2006031715A2 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101103003A (zh) 2004-11-16 2008-01-09 詹森药业有限公司 用作选择性雄激素受体调节剂(sarms)的新的杂环衍生物
US7709516B2 (en) * 2005-06-17 2010-05-04 Endorecherche, Inc. Helix 12 directed non-steroidal antiandrogens
JP5486928B2 (ja) * 2007-02-26 2014-05-07 ヴァイティー ファーマシューティカルズ,インコーポレイテッド 11β−ヒドロキシステロイドデヒドロゲナーゼ1のサイクリックウレアおよびカルバメートインヒビター
JP5451611B2 (ja) * 2007-07-26 2014-03-26 ヴァイティー ファーマシューティカルズ,インコーポレイテッド 11β−ヒドロキシステロイドデヒドロゲナーゼ1のサイクリックインヒビター
AR069207A1 (es) 2007-11-07 2010-01-06 Vitae Pharmaceuticals Inc Ureas ciclicas como inhibidores de la 11 beta - hidroxi-esteroide deshidrogenasa 1
WO2009075835A1 (en) 2007-12-11 2009-06-18 Vitae Pharmaceutical, Inc CYCLIC UREA INHIBITORS OF 11β-HYDROXYSTEROID DEHYDROGENASE 1
TW200934490A (en) * 2008-01-07 2009-08-16 Vitae Pharmaceuticals Inc Lactam inhibitors of 11 &abgr;-hydroxysteroid dehydrogenase 1
JP5490020B2 (ja) * 2008-01-24 2014-05-14 ヴァイティー ファーマシューティカルズ,インコーポレイテッド 11β−ヒドロキシステロイドデヒドロゲナーゼ1の環状カルバゼート及びセミカルバジドインヒビター
JP5734666B2 (ja) * 2008-02-11 2015-06-17 ヴァイティー ファーマシューティカルズ,インコーポレイテッド 11β−ヒドロキシステロイドデヒドロゲナーゼ1の1,3−オキサアゼパン−2−オン及び1,3−ジアゼパン−2−オン阻害剤
US8598160B2 (en) * 2008-02-15 2013-12-03 Vitae Pharmaceuticals, Inc. Cycloalkyl lactame derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
US20110105504A1 (en) * 2008-03-18 2011-05-05 Vitae Pharmaceuticals ,Inc. Inhibitors Of 11beta-Hydroxysteroid Dehydrogenase Type 1
JP5538365B2 (ja) 2008-05-01 2014-07-02 ヴァイティー ファーマシューティカルズ,インコーポレイテッド 11β−ヒドロキシステロイドデヒドロゲナーゼ1の環状阻害剤
US8242111B2 (en) * 2008-05-01 2012-08-14 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1
CL2009001058A1 (es) 2008-05-01 2010-09-10 Vitae Pharmaceuticals Inc Compuestos derivados de oxazinas sustituidas, inhibidores de la 11b-hidroxiesteroide deshidrogenasa de tipo-1; composicion farmaceutica; y uso del compuesto para inhibir la actividad de 11b-hsd1, como en el tratamiento de la diabetes, dislipidemia, hipertension, obesidad, cancer, glaucoma, entre otras.
PL2300461T3 (pl) * 2008-05-01 2013-09-30 Vitae Pharmaceuticals Inc Cykliczne inhibitory dehydrogenazy 11beta-hydroksysteroidów 1
EP2687525B1 (en) 2008-07-25 2015-09-23 Boehringer Ingelheim International GmbH Cyclic inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
CA2729998A1 (en) 2008-07-25 2010-01-28 Boehringer Ingelheim International Gmbh Inhibitors of 11beta-hydroxysteroid dehydrogenase 1
CA2729993A1 (en) 2008-07-25 2010-01-28 Boehringer Ingelheim International Gmbh Synthesis of inhibitors of 11beta-hydroxysteroid dehydrogenase type 1
GB2463514C (en) * 2008-09-11 2018-09-26 Galapagos Nv Imidazolidine compounds and uses therefor
WO2010089303A1 (en) 2009-02-04 2010-08-12 Boehringer Ingelheim International Gmbh CYCLIC INHIBITORS OF 11 β-HYDROXYSTEROID DEHYDROGENASE 1
TW201039034A (en) * 2009-04-27 2010-11-01 Chunghwa Picture Tubes Ltd Pixel structure and the method of forming the same
GEP20156309B (en) * 2009-04-30 2015-07-10 Vitae Pharmaceuticals Inc Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
UA109255C2 (ru) 2009-04-30 2015-08-10 Берінгер Інгельхайм Інтернешнл Гмбх Циклические ингибиторы 11бета-гидроксистероиддегидрогеназы 1
US8927539B2 (en) 2009-06-11 2015-01-06 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1 based on the 1,3-oxazinan-2-one structure
EP2448928B1 (en) 2009-07-01 2014-08-13 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
WO2011028112A1 (en) * 2009-09-02 2011-03-10 Valletta Health B.V. Imidazole-4-carboxylic acid for use in treating a disease related to extracellular reactive oxygen species
JP5750449B2 (ja) 2009-11-05 2015-07-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規キラルリンリガンド
AU2011212813B2 (en) 2010-02-04 2014-10-23 Radius Health, Inc. Selective androgen receptor modulators
ME02474B (me) 2010-05-12 2017-02-20 Radius Health Inc Terapijski režimi
US8648192B2 (en) 2010-05-26 2014-02-11 Boehringer Ingelheim International Gmbh 2-oxo-1,2-dihydropyridin-4-ylboronic acid derivatives
JP5860042B2 (ja) 2010-06-16 2016-02-16 ヴァイティー ファーマシューティカルズ,インコーポレイテッド 置換5、6及び7員複素環、そのような化合物を含有する医薬及びそれらの使用
WO2011161128A1 (en) 2010-06-25 2011-12-29 Boehringer Ingelheim International Gmbh Azaspirohexanones as inhibitors of 11-beta-hsd1 for the treatment of metabolic disorders
RU2434851C1 (ru) * 2010-07-22 2011-11-27 Александр Васильевич Иващенко Циклические n, n'-диарилтиомочевины или n, n'-диарилмочевины - антагонисты андрогенных рецепторов, противораковое средство, способ получения и применения
US9133182B2 (en) 2010-09-28 2015-09-15 Radius Health, Inc. Selective androgen receptor modulators
WO2012059416A1 (en) 2010-11-02 2012-05-10 Boehringer Ingelheim International Gmbh Pharmaceutical combinations for the treatment of metabolic disorders
CN104105690A (zh) * 2011-12-05 2014-10-15 诺华股份有限公司 作为雄激素受体拮抗剂的环状尿素衍生物
JP7221699B2 (ja) 2016-06-22 2023-02-14 エリプセス ファーマ エルティーディー Ar+乳癌の治療方法
CN113811333B (zh) 2019-05-14 2024-03-12 诺维逊生物股份有限公司 靶向抗癌核激素受体的化合物
TW202131930A (zh) 2019-11-13 2021-09-01 美商諾維雪碧歐公司 抗癌核荷爾蒙受體標靶化合物
US11834458B2 (en) 2021-03-23 2023-12-05 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
US12006314B2 (en) 2021-05-03 2024-06-11 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2329276A1 (fr) * 1975-10-29 1977-05-27 Roussel Uclaf Nouvelles imidazolidines substituees, procede de preparation, application comme medicament et compositions les renfermant
FR2724169B1 (fr) * 1994-09-06 1997-01-03 Roussel Uclaf Nouvelles phenylimidazolidines eventuellement substituees, leur procede et des intermediaires de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
FR2715402B1 (fr) * 1994-01-05 1996-10-04 Roussel Uclaf Nouvelles phénylimidazolines éventuellement substituées, leur procédé et des intermédiaires de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
TW521073B (en) * 1994-01-05 2003-02-21 Hoechst Marion Roussel Inc New optionally substituted phenylimidazolidines, their preparation process, their use as anti-androgenic agent and the pharmaceutical compositions containing them
US7371743B2 (en) * 2004-02-28 2008-05-13 Boehringer Ingelheim International Gmbh Carboxylic acid amides, the preparation thereof and their use as medicaments
DE102004009835A1 (de) * 2004-02-28 2005-09-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Carbonsäureamide, deren Herstellung und deren Verwendung als Arzneimittel

Also Published As

Publication number Publication date
EP1791821A2 (en) 2007-06-06
WO2006031715A3 (en) 2006-07-20
WO2006031715A2 (en) 2006-03-23
US7531565B2 (en) 2009-05-12
CN101056862B (zh) 2013-03-13
US20090215848A1 (en) 2009-08-27
CA2579514A1 (en) 2006-03-23
JP2008512492A (ja) 2008-04-24
JP5031568B2 (ja) 2012-09-19
EP1791821B1 (en) 2013-06-05
US7968580B2 (en) 2011-06-28
US20060063819A1 (en) 2006-03-23
AU2005285035B2 (en) 2012-03-22
CN101056862A (zh) 2007-10-17
AU2005285035A1 (en) 2006-03-23

Similar Documents

Publication Publication Date Title
ES2422204T3 (es) Novedosos derivados de imidazolidin-2-ona como moduladores selectivos de receptor de andrógenos (SARMS)
CO6231035A2 (es) Novedoso compuesto heteromonociclico que tiene propiedades superiores como agente farmaceutico
CO6241101A2 (es) Derivados de quinolina como inhibidores de la p13 quinasa
AR044519A1 (es) Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
DOP2010000046A (es) Compuestos de biciclolactama sustituida
AR065795A1 (es) Derivados de aza-piridopirimidinona,metodo de preparacion,medicamentos que los contienen y usos como agentes antitromboticos, antihiperlipidemicos y antidiabeticos,entre otros.
EA200701176A1 (ru) Новые соединения нафталина, способ их получения и фармацевтические композиции, содержащие их
MX2009010024A (es) Nuevo compuesto de adenina.
AR048669A1 (es) Derivados biciclicos de bisamida
AR050966A1 (es) Derivados de bencimidazol utiles como moduladores selectivos de receptores de androgenos (sarms)
AR062677A1 (es) Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden
AR065280A1 (es) Agentes antiparasitarios
AR055177A1 (es) Compuestos heterociclicos fusionados utiles como moduladores de cinasa
CR7950A (es) Sintesis de los cloruros de 4amino -2butenoilo y su uso en la preparacion of 3- cianoquinolinas
AR043508A1 (es) 1-amino 1-h-imidazoquinolinas y su uso como inmunomoduladores
MX2009012885A (es) Nuevo derivado de 1,2,3,4-tetrahidroquinoxalina que tiene, como sustituyente, grupo fenilo que tiene estructura de ester de acido sulfonico o estructura de amida de acido sulfonico introducida en este, y tiene actividad de enlace al receptor de gluco
AR077695A1 (es) Derivados de pirimidina como inhibidores del factor ixa
AR076067A1 (es) Composiciones y metodos para modular la senda de senalizacion de wnt
ECSP10010006A (es) Derivado de oxopirazina y herbicida
AR083953A1 (es) Compuestos para tratar enfermedades neurodegenerativas
AR066691A1 (es) Compuestos espiro heterociclicos derivados de imidazol. composiciones farmaceuticas.
AR067613A1 (es) Inhibidores de adn-pk, uso y sintesis de los mismos
AR056025A1 (es) Compuestos de imidazol sustituidos como inhibidores de ksp
CO5700747A2 (es) Piperidinas novedosas como moduladores de quimoquina (ccr)
AR048644A1 (es) Derivados del indol como moduladores selectivos de los receptores androgenicos (sarms)